NCT00002388已完成1 期
A Study to Evaluate the Single-Dose and Steady-State Pharmacokinetics/Dynamics of 1592U89 and Its Active Moiety, 1144U88 5'-Triphosphate (1144U88-TP) Following Six Different Dosing Regimens of 1592U89 in HIV-1 Infected Subjects
Glaxo Wellcome6 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 试验地点
- 6
研究概览
简要总结
The purpose of this study is to see if it is safe to give 1592U89 to HIV-infected patients. This study also examines the effect 1592U89 has on plasma viral load (the level of HIV in the blood).
详细描述
Cohorts of 8 patients are entered sequentially into 1 of 6 1592U89 dosing regimens. All patients receive 12 weeks of monotherapy during the initial 12-week treatment phase.
On completion of the treatment phase, patients are offered continuation therapy with 1592U89 for a minimum of 12 weeks.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Prophylaxis for opportunistic infections.
- •Patients must have:
- •HIV-1 infection.
- •CD4 cell count 100 - 500 cells/mm3 within 3 to 5 weeks prior to study drug administration.
- •No active diagnosis of AIDS (other than non-visceral Kaposi's sarcoma) according to the 1993 CDC AIDS surveillance definition.
排除标准
- •Co-existing Condition:
- •Patients with the following conditions and symptoms are excluded:
- •Malabsorption syndrome or other gastrointestinal dysfunction that may interfere with drug absorption.
- •Chronic disease such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction that in the opinion of the investigator, would compromise the safety of the patient.
- •Concurrent Medication:
- •Immunomodulating agents.
- •Chemotherapeutic agents.
- •Antiretroviral therapy. NOTE:
- •Patients who elect to continue study treatment into the extended phase may, after consultation with their primary physician, combine 1592U89 at a recommended dose of 300 mg bid with other licensed antiretroviral drugs.
- •Concurrent Treatment:
- •Radiation therapy.
- •Patients with the following prior conditions are excluded:
- •History of clinically relevant hepatitis or pancreatitis within 6 months prior to study drug administration.
- •History of hypersensitivity, anaphylactic, or idiosyncratic reaction to nucleoside analogs.
- •Prior Medication:
- •Treatment with immunomodulating or cytotoxic chemotherapeutic agents within six weeks prior to study drug administration.
- •Antiretroviral therapy within 2 weeks prior to administration of study drugs.
- •Prior Treatment:
- •Radiation therapy within six weeks prior to study drug administration. Current alcohol or illicit controlled substance use that in the opinion of the investigator, may interfere with the patient's ability to complete the study.
研究者
研究点 (6)
Loading locations...
相似试验
已完成
2 期
A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected PatientsHIV InfectionsNCT00002390Glaxo Wellcome
已完成
1 期
Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)HIV-1 InfectionNCT03188523Merck Sharp & Dohme LLC12
已完成
1 期
MK-8583 Single Dose Study in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8583-002)HIV-1 InfectionNCT03552536Merck Sharp & Dohme LLC5
已完成
1 期
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89HIV InfectionsNCT00002141Burroughs Wellcome18
已完成
1 期
Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)HIV-1 InfectionNCT03351699Merck Sharp & Dohme LLC24